Latest News on RMD

Financial News Based On Company


Advertisement
Advertisement

ResMed Director Jan De Witte Sells 429 Shares at $237 Under Rule 10b5-1 Plan

https://kalkine.com.au/news/announcements/resmed-director-jan-de-witte-sells-429-shares-at-237-under-rule-10b5-1-plan
ResMed Inc (ASX:RMD) director Jan De Witte sold 429 shares of the company's common stock at $237 per share on November 17, 2026. This transaction was executed under a Rule 10b5-1 trading plan adopted on August 19, 2026. Following the sale, De Witte directly holds 3,772 shares of ResMed common stock.

ResMed director Ronald Taylor retires from board

https://www.tradingview.com/news/tradingview:1a793ed58f07f:0-resmed-director-ronald-taylor-retires-from-board/
Ronald Taylor, a director at ResMed (RMD), retired from the company's board after his term ended at the November 18, 2026 annual meeting and he did not seek re-election. His departure reduces the board size from 11 to 10 directors. This information is based on an SEC 8-K filing from November 19, 2026.

Three years of results could put ResMed (RMD) executives at twice their FY2027 stock award targets.

https://www.stocktitan.net/sec-filings/RMD/8-k-resmed-inc-reports-material-event-1cbc98b465aa.html
ResMed Inc. (RMD) has approved a revised performance-based restricted stock unit design and grants for its named executive officers for FY2027. These awards are tied to Adjusted EPS and Adjusted Revenue over three fiscal years, with a relative total shareholder return modifier, and are capped at 200% of the target payout. Additionally, stockholders elected ten directors, ratified PricewaterhouseCoopers LLP as the independent auditor, and approved executive compensation on an advisory basis at the annual meeting.

IDEXX Laboratories, Inc. (IDXX) Stock forecasts

https://uk.finance.yahoo.com/research/reports/ARGUS_4071_QuantitativeReport_1794960000000
Argus has lowered its target price for IDEXX Laboratories, Inc. (IDXX) to $759.00 from its current price of $689.65. The report, published on November 18, 2026, focuses on IDXX, a company that develops, manufactures, and distributes diagnostic products and services for pets and livestock within the healthcare sector.

STERIS plc (Ireland) (STE) Stock forecasts

https://sg.finance.yahoo.com/research/reports/ARGUS_4272_QuantitativeReport_1794960000000
This article provides a brief overview of STERIS plc (STE), an Ireland-domiciled medical technology company specializing in sterilization services and infection prevention. It highlights an Argus report from November 18, 2026, which includes a current price of $254.76 for STE and offers access to a full report with a price target. The article also lists other related analyst reports for various companies.
Advertisement

How Resmed Inc. (RMD) Affects Rotational Strategy Timing

https://news.stocktradersdaily.com/news_release/15/How_Resmed_Inc._RMD_Affects_Rotational_Strategy_Timing_111926102601_1795101961.html
This article analyzes Resmed Inc. (RMD) from a rotational strategy perspective, highlighting divergent sentiment and resistance testing. It provides three AI-generated trading strategies—Position Trading (long), Momentum Breakout (breakout), and Risk Hedging (short)—with specific entry, target, and stop-loss levels, along with a multi-timeframe signal analysis.

Form 4 ResMed Inc: Jan De Witte (Director) For: 17 November

https://in.investing.com/news/stock-market-news/form-4-resmed-inc-jan-de-witte-director-for-17-november-93CH-5713784
This article reports on a Form 4 filing for ResMed Inc., specifically detailing an action by Director Jan De Witte on November 17th. Form 4 filings are mandatory reports that must be submitted to the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the ownership of company stock by an insider. The article, published by Investing.com, indicates this as a piece of insider trading news.

Form 4 ResMed Inc: Jan De Witte (Director) For: 17 November

https://ca.investing.com/news/stock-market-news/form-4-resmed-inc-jan-de-witte-director-for-17-november-93CH-4968183
This article reports on a Form 4 filing for ResMed Inc. (RMD) concerning director Jan De Witte. The filing is related to activity on November 17th. The brief piece indicates that this is a standard disclosure of insider transactions.

Form 4 ResMed Inc: Jan De Witte (Director) For: 17 November

https://uk.investing.com/news/stock-market-news/form-4-resmed-inc-jan-de-witte-director-for-17-november-93CH-4991863
This article reports on a Form 4 filing for ResMed Inc., indicating that Jan De Witte, a director, made a transaction on November 17th. The specific details of the transaction are not provided in the snippet, but it highlights an insider trading event. The article was published on November 18, 2026, at 23:20 UTC.

Why Are ResMed (ASX:RMD), Commonwealth Bank and BHP Blue Chips in Focus?

https://kalkinemedia.com/au/stocks/bluechip/why-are-resmed-asxrmd-commonwealth-bank-and-bhp-blue-chips-in-focus
This article examines three prominent Australian blue-chip companies: ResMed (ASX:RMD), Commonwealth Bank (ASX:CBA), and BHP (ASX:BHP). It highlights their recent financial updates and business activities, noting how each company operates in distinct industries—sleep health technology, banking, and resources—and is analyzed using different performance metrics.
Advertisement

ResMed (RMD) director plans to sell 429 shares acquired through stock vesting.

https://www.stocktitan.net/sec-filings/RMD/144-resmed-inc-sec-filing-ef3589c3e925.html
ResMed Inc. (RMD) director Jan De Witte has reported a planned sale of 429 common shares, valued at approximately $101,673.00, with an anticipated sale date of November 17, 2026. These shares were acquired on November 11, 2026, through restricted stock vesting as compensation. The sale plan was adopted or instructed on August 19, 2026, under Rule 10b5-1.

North America Bioprocessing Technology Market Companies, Size & Trends 2026-2035

https://www.precedenceresearch.com/north-america-bioprocessing-technology-market
The North America bioprocessing technology market, valued at USD 13.59 billion in 2026, is projected to reach USD 31.01 billion by 2035, growing at a CAGR of 9.60%. This growth is driven by expanding biologics pipelines, onshoring investments, CDMO expansion, and the scaling of cell and gene therapies. Key players include Thermo Fisher Scientific, Cytiva (Danaher), and Merck KGaA (MilliporeSigma), with consumables and single-use systems dominating the product segment and the U.S. leading the market regionally.

4DMedical (ASX: 4DX) Adds Former ResMed CFO Brett Sandercock to Board Ahead of US Commercial Scaling

https://kalkine.com.au/news/healthcare/4dmedical-asx-4dx-adds-former-resmed-cfo-brett-sandercock-to-board-ahead-of-us-commercial-scaling
4DMedical (ASX:4DX) has appointed Brett Sandercock, former CFO of ResMed, as an independent Non-Executive Director. This strategic appointment aims to bolster 4DMedical's financial oversight, governance, and healthcare capital markets experience as it scales its XV Technology platform into the US market. Sandercock will chair the Audit and Risk Committee, bringing over three decades of finance leadership from his tenure at ResMed.

Form 4 ResMed Inc: Aaron Bloomer (CFO) For: 11 November By Investing.com

https://ng.investing.com/news/stock-market-news/form-4-resmed-inc-aaron-bloomer-cfo-for-11-november-93CH-2807924
This article reports on a Form 4 filing for ResMed Inc. (RMD) concerning its CFO, Aaron Bloomer. The filing details transactions that occurred on November 11th. The article is a brief financial news update provided by Investing.com.

Form 4 ResMed Inc: Aaron Bloomer (CFO) For: 11 November By Investing.com

https://au.investing.com/news/stock-market-news/form-4-resmed-inc-aaron-bloomer-cfo-for-11-november-93CH-4771092
This article reports on a Form 4 filing for ResMed Inc., specifically detailing a transaction involving Aaron Bloomer, the Chief Financial Officer. The filing pertains to activity on November 11 and was published by Investing.com. The content primarily serves as an announcement of this insider trading disclosure.
Advertisement

Form 4 ResMed Inc: Aaron Bloomer (CFO) For: 11 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-4-resmed-inc-aaron-bloomer-cfo-for-11-november-93CH-4982621
This article reports on a Form 4 filing for ResMed Inc. concerning Chief Financial Officer Aaron Bloomer. The filing pertains to activity on November 11th and was published by Investing.com. It indicates that the CFO's transactions are of interest to financial markets.

Edwards Lifesciences Corporation (EW) stock price, news, quote and history

https://sg.finance.yahoo.com/quote/EW/
Edwards Lifesciences Corporation (EW) stock is currently trading at $107.15, up 1.28%, with an after-hours price of $106.50. The company, a medical device provider specializing in cardiovascular diseases, has seen a YTD return of 25.69% and a 1-year return of 24.43%. Analysts have an average price target of $113.39, with TD Cowen recently raising its price target to $121 and maintaining a Buy rating.

ResMed CEO Reports Option Exercises and Share Sale

https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/8829779/resmed-ceo-reports-option-exercises-and-share-sale/
ResMed's Chairman and CEO, Michael J. Farrell, recently exercised options for 4,993 common shares at $146.34 each and subsequently sold all of these shares at a weighted-average price of $235.3473. Following these transactions, Farrell holds 479,803 direct shares and 2,090 indirect shares through a family trust. Analysts currently rate ResMed (AU:RMD) with a Buy and a A$38.70 price target.

Here's How Much $100 Invested In ResMed 10 Years Ago Would Be Worth Today

https://www.benzinga.com/news/26/11/63270211/here-s-how-much-100-invested-resmed-10-years-ago-would-be-worth-today
An investment of $100 in ResMed (NYSE: RMD) made 10 years ago would be worth $414.70 today, demonstrating the power of compounded returns. Over the past decade, ResMed has outperformed the market by 1.92% on an annualized basis, achieving an average annual return of 15.08%. The company currently holds a market capitalization of $33.60 billion.

Form 4 ResMed Inc: Michael J. Farrell (Director, Chairman and CEO) For: 11 November

https://ca.investing.com/news/stock-market-news/form-4-resmed-inc-michael-j-farrell-director-chairman-and-ceo-for-11-november-93CH-4957753
This article reports on a Form 4 filing for ResMed Inc. indicating transactions by Michael J. Farrell, who serves as a Director, Chairman, and CEO of the company. The filing pertains to activities that occurred on November 11th. No specific details of the transactions are provided beyond the fact of the filing.
Advertisement

Form 4 ResMed Inc: Michael J. Farrell (Director, Chairman and CEO) For: 11 November

https://uk.investing.com/news/stock-market-news/form-4-resmed-inc-michael-j-farrell-director-chairman-and-ceo-for-11-november-93CH-4981860
The article reports on a Form 4 filing for ResMed Inc. concerning Michael J. Farrell, who serves as a Director, Chairman, and CEO. The filing pertains to activity on November 11. This indicates a mandatory disclosure of changes in ownership of company stock by an insider.

Form 4 ResMed Inc: Jan De Witte (Director) For: 11 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-resmed-inc-jan-de-witte-director-for-11-november-93CH-5703525
This article reports a Form 4 filing for ResMed Inc., indicating a transaction by Director Jan De Witte on November 11. These filings are mandatory for company insiders to disclose changes in their ownership of securities. The brief note highlights the disclosure of an insider transaction.

Form 4 ResMed Inc: Michael J. Rider (Global General Counsel) For: 11 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-resmed-inc-michael-j-rider-global-general-counsel-for-11-november-93CH-5702474
This article reports a Form 4 filing for ResMed Inc. concerning Michael J. Rider, the Global General Counsel. The filing was made for November 11.

Form 4 ResMed Inc: Michael J. Rider (Global General Counsel) For: 11 November

https://ca.investing.com/news/stock-market-news/form-4-resmed-inc-michael-j-rider-global-general-counsel-for-11-november-93CH-4956196
This article reports on a Form 4 filing for ResMed Inc. concerning Michael J. Rider, the company's Global General Counsel, for transactions occurring on November 11. Form 4 filings disclose changes in beneficial ownership of securities by company insiders. The article indicates that ResMed Inc. has a stock symbol RMD.

Form 4 ResMed Inc: Michael J. Rider (Global General Counsel) For: 11 November

https://uk.investing.com/news/stock-market-news/form-4-resmed-inc-michael-j-rider-global-general-counsel-for-11-november-93CH-4980363
This article reports on a Form 4 filing for ResMed Inc., specifically noting activity by Michael J. Rider, the company's Global General Counsel, on November 11. Form 4 documents are used to report changes in beneficial ownership of company stock by insiders. The article indicates a publication date of November 13, 2026, at 11:32.
Advertisement

ResMed (ASX:RMD) Shares in Focus: Why Is the ASX 50 Stock on the Radar?

https://kalkinemedia.com/au/stocks/healthcare/resmed-asxrmd-shares-in-focus-why-is-the-asx-50-stock-on-the-radar
This article examines why ResMed (ASX:RMD) is attracting attention, highlighting its position within the ASX 50 and ASX 200 benchmarks. It discusses the importance of operating evidence, such as customer behavior and project milestones, over short-term market sentiment. The piece also touches on potential sources of support like clinical demand and product adoption, as well as risks including regulatory requirements and cost pressures.

CNSY - Cerenome Inc. stock news, filings & ratings | Quantisnow

https://www.quantisnow.com/company/CNSY
Cerenome Inc. (CNSY) is a CNS oncology company listed on NASDAQ, specializing in precision diagnostics, targeted therapeutics, and AI for central nervous system cancers. The company's stock recently saw a significant jump (+46.65%) and has been active with news including a new Chief Business Officer appointment, an in-network agreement with Aetna for its CNSide® Diagnostics platform, and an upcoming conference call to discuss clinical data and Q3 2026 financial results. Financially, Cerenome reported $4.20M in revenue for the last twelve months and a net loss of $26.09M.

EnerSys earnings rise as tax credits and defense demand support margins

https://finchannel.com/enersys-earnings-rise-as-tax-credits-and-defense-demand-support-margins/141315/american-business-trends/stock-prices/2026/11/
EnerSys reported an increase in fiscal second-quarter earnings, driven by stronger margins and manufacturing tax credits, despite sales remaining flat. The company is also advancing its defense business expansion with the proposed acquisition of Ultralife. Management expects continued strength in aerospace, defense, and data centers, while material handling remains a recovery market.

Can REA Group (ASX:REA), ResMed and Wesfarmers Stay Strong for the Long Run?

https://kalkinemedia.com/au/stocks/bluechip/can-rea-group-asxrea-resmed-and-wesfarmers-stay-strong-for-the-long-run
This article examines REA Group (ASX:REA), ResMed (ASX:RMD), and Wesfarmers (ASX:WES) as potential long-term investments, highlighting their strong market positions and growth drivers. REA Group benefits from its dominant property website, ResMed from recurring demand for sleep apnoea devices, and Wesfarmers from its diversified retail brands. However, each company faces risks such as regulation, competition, and consumer spending pressures.

INSP Is Up 12.1% in Three Months: Can Its Rally Continue From Here?

https://www.tradingview.com/news/zacks:c7d8bba59094b:0-insp-is-up-12-1-in-three-months-can-its-rally-continue-from-here/
Inspire Medical Systems (INSP) shares have risen 12.1% in the past three months despite ongoing reimbursement issues. While Q3 2026 revenues and adjusted EPS declined year-over-year, they still surpassed Zacks Consensus Estimates and showed sequential improvement. The company's 2027 recovery plan, Project Horizon, focuses on patient engagement and education to stabilize growth, with valuation suggesting potential for multiple expansion if these efforts succeed.
Advertisement

Industries affected by GLP-1 drugs: 10 winners and losers

https://qz.com/industries-affected-glp1-drugs-winners-losers
GLP-1 drugs like Ozempic and Zepbound are significantly impacting various industries, creating winners such as drugmakers (Eli Lilly, Novo Nordisk) and contract manufacturers, while posing challenges for others. Commercial weight-loss programs like WW International have faced bankruptcy, and packaged food, alcohol, and restaurant sectors are anticipating reduced sales due to decreased appetite among users. The drugs also offer a non-surgical alternative to bariatric surgery and could affect CPAP machine makers, while employers and insurers grapple with the rising costs of coverage.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of ResMed Inc. (NYSE: RMD).

https://www.prnewswire.com/news-releases/shareholder-alert-levi--korsinsky-llp-notifies-shareholders-of-an-investigation-concerning-possible-breaches-of-fiduciary-duties-by-certain-officers-and-directors-of-resmed-inc-nyse-rmd-302933929.html
Levi & Korsinsky, LLP has announced an investigation into ResMed Inc. (NYSE: RMD) regarding potential breaches of fiduciary duties by certain officers and directors. Current shareholders of RMD are encouraged to seek additional information about the investigation. The firm specializes in securities litigation and aims to recover losses for aggrieved shareholders.

Form 144 RESMED INC For: 9 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-resmed-inc-for-9-november-93CH-4944365
This article reports on the filing of Form 144 by RESMED INC on November 9, 2026. Form 144 is a notice of the intent to sell restricted securities. The brief article, published by Investing.com, indicates this financial action by the company.

Form 144 RESMED INC For: 9 November By Investing.com

https://in.investing.com/news/stock-market-news/form-144-resmed-inc-for-9-november-93CH-5691826
This article reports the filing of Form 144 for RESMED INC on November 9th. Form 144 is a notice of the proposed sale of restricted securities. The brief article, published by Investing.com, provides no further details beyond the filing announcement.

Form 144 RESMED INC For: 9 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-144-resmed-inc-for-9-november-93CH-4969567
This article from Investing.com announces the filing of Form 144 for RESMED INC on November 9, 2026. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider activity for the company. The article provides the title and date of the filing, along with a link to view comments.
Advertisement

Should You Buy ResMed Inc. (NYSE:RMD) For Its Upcoming Dividend?

https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/should-you-buy-resmed-inc-nysermd-for-its-upcoming-dividend-1
ResMed Inc. (NYSE:RMD) is set to trade ex-dividend in the next four days, with a payment of US$0.66 per share, contributing to a trailing yield of 1.1%. The company demonstrates strong dividend sustainability, with conservative payout ratios of 22% from both net income and free cash flow. ResMed also shows robust earnings growth, up 28% annually over the past five years, and has consistently increased its dividend by approximately 8.2% per year over the last decade, making it an attractive prospect for dividend-focused investors.

ResMed Inc. (RMD) Seasonal returns chart

https://au.finance.yahoo.com/quote/RMD/seasonality/
The article provides a seasonal returns chart for ResMed Inc. (RMD) on Yahoo Finance. However, it states that seasonality data is currently unavailable for RMD. The page also includes real-time stock price information and links to other financial data for the company.

Inogen’s new CEO sets sights on ‘simpler’ company

https://www.hmenews.com/article/inogen-s-new-ceo-sets-sights-on-simpler-company
Andy Reding, Inogen's new President and CEO, aims to simplify the company, strengthen execution, and return it to profitable growth. Key initiatives include the divestiture of its U.S. oxygen rental business to Rotech Healthcare for up to $24.8 million and implementing an additional $20 million cost-reduction program. Inogen reported a 3.8% increase in U.S. sales in the third quarter, its first year-over-year growth since Q4 2024.

Healthcare Stocks on ASX Today: Fisher & Paykel Healthcare Corporation, Pro Medicus and Resmed Inc Shares Move Across the Sector

https://kalkine.com.au/news/healthcare/healthcare-stocks-on-asx-today-fisher-paykel-healthcare-corporation-pro-medicus-and-resmed-inc-shares-move-across-the-sector
On November 6, 2026, Fisher & Paykel Healthcare Corporation Ltd (FPH) and Resmed Inc (RMD) saw slight gains on the ASX, rising 0.80% and 0.41% respectively, while Pro Medicus Ltd (PME) declined by 1.49%. The broader S&P/ASX 200 Health Care index eased 0.20%. The article highlights recent company announcements, including FPH's FY27 guidance, PME's new contracts, and RMD's Q1 FY27 financial results.

ResMed (ASX:RMD) Slides Despite a Solid Quarter: Why?

https://kalkinemedia.com/au/stocks/bluechip/resmed-asxrmd-slides-despite-a-solid-quarter-why
ResMed's stock fell sharply despite reporting strong September-quarter revenue and earnings, led by sleep devices and masks. The market reaction is attributed to high expectations, slightly softer operating margins, weaker cash flow, and unchanged full-year guidance, even though the company's core business and capital returns remain robust. The long-term impact of weight-loss medicines on sleep apnoea demand also remains a background concern.
Advertisement

AIA Group Ltd Sells 10,019 Shares of AMETEK, Inc. $AME

https://www.marketbeat.com/instant-alerts/filing-aia-group-ltd-sells-10019-shares-of-ametek-inc-ame-2026-11-05/
AIA Group Ltd reduced its stake in AMETEK, Inc. (NYSE:AME) by 29.1%, selling 10,019 shares, though its remaining holdings are valued at over $6 million. Other institutional investors showed mixed activity, with some increasing and others adjusting their positions. The article also highlights AMETEK's strong Q3 results, raised 2026 outlook, and analyst price target adjustments, alongside a recent insider stock sale.

ResMed Inc. stock rises Wednesday, outperforms market

https://www.marketwatch.com/data-news/resmed-inc-stock-rises-wednesday-outperforms-market-a41d4446-03aff3defa93
ResMed Inc. (RMD) saw its stock advance by 5.91% to $240.51 on Wednesday, outperforming the broader market. The S&P 500 Index rose 1.58%, and the Dow Jones Industrial Average increased by 3.03%. Despite the gain, ResMed Inc. closed 13.38% below its 52-week high.

After repaying 99% of its third-party debt, Genius Group seeks an Australian listing.

https://www.stocktitan.net/news/GNS/genius-group-advances-asx-dual-listing-expands-geniu-spark-ai-data-9vyc26tf433f.html
Genius Group (NYSE American: GNS) announced its board has approved proceeding with a formal application for a dual listing on the Australian Securities Exchange (ASX) via CHESS Depositary Interests. This decision follows the company achieving a positive net working capital surplus in October 2026, alongside significant financial improvements including repaying 99% of third-party debt and reducing total liabilities by 37% in the first half of the year. Additionally, the company is expanding its GENIUSpark AI data center initiative to Australia, intending for Canadian and Australian launches to pilot further developments in Southeast Asia.

ResMed Inc. $RMD Shares Sold by Sumitomo Mitsui Trust Group Inc.

https://www.marketbeat.com/instant-alerts/filing-resmed-inc-rmd-shares-sold-by-sumitomo-mitsui-trust-group-inc-2026-11-04/
Sumitomo Mitsui Trust Group Inc. reduced its stake in ResMed Inc. (NYSE:RMD) by 3.3% during the third quarter, selling 11,350 shares but still retaining a significant holding valued at $74.4 million. Despite the sale, institutional investors and hedge funds collectively own 54.98% of the stock. ResMed recently exceeded quarterly earnings expectations with an EPS of $2.91 and revenue of $1.41 billion, and declared a quarterly dividend of $0.66 per share.

ResMed Inc. (RMD) Stock forecasts

https://uk.finance.yahoo.com/research/reports/ARGUS_4219_QuantitativeReport_1791331200000
Argus lowered its target price for ResMed Inc. (RMD) to $243.00, while the current price stands at $227.08. ResMed is a leading global provider of respiratory care devices, specializing in products for sleep apnea treatment. The report also highlights other related analyst reports for various companies.
Advertisement

ResMed or Cochlear: Which ASX healthcare share would I buy today?

https://www.fool.com.au/2026/11/04/resmed-or-cochlear-which-asx-healthcare-share-would-i-buy-today/
The article compares two leading ASX healthcare shares, ResMed (ASX: RMD) and Cochlear (ASX: COH), evaluating their recent financial performance, growth opportunities, and valuations. While both companies are seen as long-term buys, the author concludes that ResMed offers a better buying opportunity currently due to its stronger earnings growth and more attractive valuation. ResMed's Q1 results showed robust revenue and EPS growth, whereas Cochlear is still working towards an earnings recovery.

Earnings to watch: iRhythm (IRTC) reports Q3 results tomorrow

https://www.tradingview.com/news/stockstory:86fabb918094b:0-earnings-to-watch-irhythm-irtc-reports-q3-results-tomorrow/
iRhythm Technologies (IRTC) is set to announce its Q3 earnings results, with analysts expecting a 15.3% year-on-year revenue growth. The company has a history of exceeding Wall Street's expectations and reported strong Q2 results, beating revenue and EPS estimates. Positive sentiment is noted in the healthcare equipment and supplies segment, with iRhythm's shares up 15.8% over the last month.

ResMed Inc Reports Net Reduction of 10,680,280 CDIs on Issue for October 2026

https://kalkine.com.au/news/announcements/resmed-inc-reports-net-reduction-of-10680280-cdis-on-issue-for-october-2026
ResMed Inc (ASX:RMD) announced a net reduction of 10,680,280 CHESS Depositary Interests (CDIs) on issue for October 2026, bringing the total to 559,448,020 CDIs. This change was primarily due to net transfers of securities between CDIs and common stock quoted on the NYSE. The company also reported movements in related securities (RMDAB and RMDAA) attributed to transfers, new share issues from employee equity plans, and share repurchases.

Insulet (PODD) Q3 earnings: what to expect

https://www.tradingview.com/news/stockstory:78f91b7e7094b:0-insulet-podd-q3-earnings-what-to-expect/
Insulet (PODD) is set to report its Q3 earnings this Wednesday, with the market expecting a 17.8% year-on-year revenue growth, a slowdown from the previous year. The company has a history of surpassing Wall Street's expectations and has seen positive investor sentiment, with its stock up 13.6% over the last month, outperforming the healthcare equipment and supplies segment average.

ResMed Inc. stock rises Monday, outperforms market

https://www.marketwatch.com/data-news/resmed-inc-stock-rises-monday-outperforms-market-4d7ee173-cda62a28ef81
ResMed Inc. (RMD) shares increased by 1.30% to $232.94 on Monday, outperforming the mixed market session where the Dow Jones Industrial Average rose and the S&P 500 Index fell. The company's stock closed 16.11% below its 52-week high of $277.67, achieved on February 10th.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement